BVXV News and Press, BiondVax Pharmaceuticals Ltd. From 08/25/22

BiondVax announces Second Quarter 2022 Financial Results and Provides Business Update PR Newswire JERUSALEM , Aug. 25, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), which focuses on developing, manufacturing and commercializing in...

BiondVax Pharmaceuticals ( NASDAQ: BVXV ) on Wednesday said the European Investment Bank (EIB) had formally approved new terms to the outstanding €24M loan to the Israeli biopharmaceutical company. The new terms include: An extension of the maturity dates fr...

BiondVax and European Investment Bank sign definitive amendment extending maturity of loan until December 2027 with additional terms in support of BiondVax's new strategy PR Newswire JERUSALEM , Aug. 10, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd...

Hyzon Motors ( HYZN ) -36% after disclosing operational inefficiencies, financial issues . Helius Medical Technologies ( HSDT ) -30% . Quoin Pharmaceuticals ( QNRX ) -23% . Chembio Diagnostics ( CEMI ) -18% on Q2 earnings release . ...

BiondVax Pharmaceuticals (NASDAQ:BVXV) on Tuesday said it got supportive scientific advice from Germany's Paul Ehrlich Institute (PEI) for its development plans for its COVID-19 therapy. PEI scientific advice is generally considered a first key step towards regulatory approval. PEI suppo...

BiondVax receives supportive Scientific Advice from the Paul Ehrlich Institute (PEI) for COVID-19 NanoAb development plans including first-in-human Phase 1/2a safety and efficacy clinical trial PR Newswire PEI supports BiondVax's plan for first-in-human clinical trial ...

Biondvax Pharmaceuticals press release (NASDAQ:BVXV): Q1 GAAP EPS of -NIS0.02. Cash and cash equivalents NIS48.89M. For further details see: Biondvax Pharmaceuticals reports Q1 results

BiondVax Announces First Quarter 2022 Financial Results and Provides Business Update PR Newswire JERUSALEM , June 1, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceuticals company focused on developing, manufacturing a...

BiondVax to Present at H.C. Wainwright Global Investment Conference PR Newswire JERUSALEM , May 19, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing...

BiondVax Provides Update at Biomed Israel Conference and Announces Significant Progress in its Nanosized Antibodies Program PR Newswire JERUSALEM , May 12, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) , a biopharmaceutical com...